CEO Pascal Soriot says he does not expect the additional trial to hold up regulatory approvals in the UK and EU, while clearance from the US FDA may take longer
Netcare CEO Richard Friedland talks to Business Day TV about the health of the group’s balance sheet
Private hospital group attributes its headline loss and revenue plunge largely to Covid-19
Life Healthcare group CEO Peter Wharton-Hood talks to Business Day TV about the group’s full-year financial performance
Group estimates it has lost about R3.7bn in revenue due to the coronavirus pandemic
The group estimates the first wave of the pandemic cost its Southern African operations R2.3bn in lost revenue, but it’s now better prepared
Moderna shares surge as much as 15% as it becomes the second US drugmaker to report results that far exceed expectations
The private hospital group’s operations in Switzerland and the Middle East have bounced back
SPONSORED | Herbalife Nutrition products are designed to help health enthusiasts achieve their goals
Industry peers block expansion of low-cost benefit options; no new members to be enrolled
Dis-Chem CFO Rui Morais talks to Business Day TV about the group’s annual financial results
SPONSORED | Business Day Dialogue in partnership with ASI on the future of health care in SA
In an unusual move, the US Food and Drug Administration combines its reviewers’ findings with Biogen’s in one document ahead of meeting on the drug
Aspen Pharmacare CEO Stephen Saad talks to Business Day TV about its preliminary agreement with Johnson & Johnson
Agreement will enable drugmaker to use spare manufacturing capacity and bring down overhead costs, says CEO
SPONSORED | The impact on future income disability rates, may be influenced by the state of the economy
Investment company says sale of stake in hospitals group will raise R1.35bn which will be used to reduce debt in an uncertain economy
Purdue formally admitted to criminal conduct related to distribution of its painkillers and agreed to pay $225m to resolve US justice department investigations
Diagnostics boom helps the Swiss drug company stick to its 2020 targets
Covid-19 weighed on the group in the six months to end-September, but Mediclinic has seen a rebound in trading since May
